Clinical Trials Directory

Trials / Completed

CompletedNCT06610045

The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study

Status
Completed
Phase
Study type
Observational
Enrollment
400 (actual)
Sponsor
PeriPharm · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The purpose of this observational study is to estimate the burden of multiple myeloma on patients and caregivers in terms of QoL. Additionally, this study will assess the correlation between QoL, obtained from commonly used and validated questionnaires, and the perceptions of both patients and caregivers respectively., obtain from a 10-point scale and a comment box.

Detailed description

Potential participants will be identified by Myeloma Canada using their database. Myeloma Canada is a registered non-profit organization created by, and for, Canadians impacted by multiple myeloma. As part of Myeloma Canada website, patients and caregivers can subscribe to a mailing list to receive their monthly newsletter and to participate in surveys. This database comprises about 5,000 individuals, including patients and caregivers. An e-mail will be sent to 600 patients and 200 caregivers randomly selected to invited them to participate in the survey. Interested participants will be invited to visit the Participant Portal on the PROxy website (https://periproxy.com/en), to sign the informed consent form and complete online questionnaires. Upon request, paper-based documents (i.e., informed consent form and questionnaires) can also be sent by mail. The following questionnaires will be used: Patients * Patient Information Questionnaire (i.e., baseline characteristics) * EORTC QLQ-C30 * EORTC QLQ-MY20 * EQ-5D-5L * ESAS-R * Patients Perspective Caregivers * Caregiver Information Questionnaire (i.e., baseline characteristics) * CarGOQoL * Caregivers Perspective If the sample size (i.e., 300 patients and 100 caregivers) is not reached one month after the first e-mail, an invitation e-mail will be sent to an additional 600 eligible patients and/or 200 caregivers randomly selected. This scheme of participant identification will be performed until the sample size is reached.

Conditions

Interventions

TypeNameDescription
OTHERNo interventionNo specific intervention is assess in this study.

Timeline

Start date
2024-10-15
Primary completion
2025-02-24
Completion
2025-03-12
First posted
2024-09-24
Last updated
2025-03-13

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT06610045. Inclusion in this directory is not an endorsement.